Why the study?
Does mini-intensity warfarin (target INR 1.3-1.6) suppress prothrombin activation and can it be reliably monitored using a sensitive thromboplastin in patients with prior cerebrovascular events?
Population
21 patients with a history of cerebrovascular events, mean age 61 years.
Comparison
Warfarin targeting an INR range of 1.3 to 1.6… vs Baseline measurements and lower sensitivity…
Design
Cohort
Follow-up
several months
Authors
Loading...
Mini-intensity warfarin may suppress prothrombin activation with sensitive monitoring; hypothesis-generating for cerebrovascular prevention trials.
Does mini-intensity warfarin (target INR 1.3-1.6) suppress prothrombin activation and can it be reliably monitored using a sensitive thromboplastin in patients with prior cerebrovascular events?
Mini-intensity warfarin (target INR 1.3-1.6) significantly suppresses prothrombin activation in vivo and can be reliably monitored using a highly sensitive thromboplastin.
Millenson et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: